The Centers for Medicare and Medicaid Services (CMS) sent agreements to drug manufacturers yesterday about the 50% brand name drug discounts they’ll be offering next year to beneficiaries in the coverage gap, as part of the Affordable Care Act signed by the President in March. Drug manufacturers must sign the agreement by Sept. 1 in order to continue offering drugs through the Medicare Part D program. The agreement also outlines a dispute resolution and appeals process to be used for payment discrepancies or conflicts raised by the manufacturers. In addition, CMS will be conducting extensive editing on payment data to make sure beneficiaries receive their entitled discounts.
See CMS’ press release for more information.
For more information on health care reform and Medicare, see our article, What Does Health Care Reform Mean for Medicare Beneficiaries? Summary of Key Provisions.
For more information on Part D, see our section Prescription Drugs.
